ASCO 2022: KEYNOTE-716 Update Confirms Benefits of Adjuvant Pembrolizumab in Stage IIB/IIC Melanoma
Both recurrence-free and distant metastasis-free survival were better with pembrolizumab than placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.